Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL-ESIDRIX #2 vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension
Hypertension
1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Reserpine: 50-100 hours (biphasic; terminal phase 11-16 days due to slow release from adrenergic storage sites); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment).
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Reserpine is extensively metabolized in the liver via hydrolysis and conjugation, with metabolites excreted in urine and feces. Hydrochlorothiazide is not metabolized extensively; it is primarily eliminated unchanged by the kidneys.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Reserpine: 60% renal (as metabolites), 40% fecal (as parent drug and metabolites); Hydrochlorothiazide: >95% renal (unchanged) via tubular secretion.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Reserpine: 96% bound to albumin; Hydrochlorothiazide: 40-68% bound to albumin.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Reserpine: 5-8 L/kg (extensive tissue binding, particularly to adrenergic neurons); Hydrochlorothiazide: 0.83-1.14 L/kg (distributes into extracellular fluid).
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Reserpine: 50-60% (oral, extensive first-pass metabolism); Hydrochlorothiazide: 65-75% (oral, with food decreasing absorption by 10-20%).
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Contraindicated if GFR < 30 m L/min. For GFR 30-59 m L/min, maximum dose is 1 tablet every other day due to hydrochlorothiazide accumulation.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: caution, consider reducing dose. Child-Pugh B: contraindicated due to risk of hepatic coma and reserpine-induced depression. Child-Pugh C: contraindicated.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended for children. Safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Initiate with 0.5 tablet once daily due to increased sensitivity to reserpine (CNS depression) and hydrochlorothiazide (hypotension, electrolyte imbalance). Titrate slowly.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
Reserpine may cause depression, and should be discontinued if symptoms occur; use with caution in patients with history of depression.,Hydrochlorothiazide may cause electrolyte imbalances (e.g., hypokalemia), dehydration, and increased serum uric acid and glucose.,May cause orthostatic hypotension, especially with alcohol or other antihypertensives.,Renal impairment: monitor renal function.,Hepatic impairment: use with caution as reserpine may precipitate hepatic encephalopathy.,Sulfonamide allergy: hydrochlorothiazide is a sulfonamide derivative; cross-sensitivity may occur.,May require dosage adjustment in renal impairment.,Avoid abrupt discontinuation of reserpine; taper gradually.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to reserpine, hydrochlorothiazide, or sulfonamides.,History of mental depression or suicidal tendencies.,Active peptic ulcer or ulcerative colitis.,Electroconvulsive therapy (ECT) within 7 days.,Anuria or severe renal impairment (e.g., creatinine clearance <30 m L/min).,Pheochromocytoma (reserpine may paradoxically increase blood pressure).
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
High-potassium foods (bananas, oranges, spinach) may increase risk of hyperkalemia if used with potassium-sparing diuretics; however, hydrochlorothiazide is potassium-wasting, so hypokalemia risk exists. Avoid excessive sodium intake (processed foods, salt) as it can reduce antihypertensive effect. Grapefruit juice may interact with reserpine; limit consumption.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
Serpasil (reserpine) is classified as FDA Pregnancy Category C. Reserpine crosses the placenta. First trimester: Limited human data, but animal studies suggest increased risk of skeletal and cardiovascular anomalies. Second and third trimesters: Possible adverse effects including neonatal respiratory depression, bradycardia, hypothermia, and hypotonia. Esidrix (hydrochlorothiazide) is FDA Pregnancy Category B; however, thiazide diuretics may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use only if clearly needed.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Reserpine is excreted into breast milk; M/P ratio not established. Potential for severe adverse effects in nursing infants including respiratory depression, bradycardia, and hypotonia. Hydrochlorothiazide is excreted in breast milk in low amounts (M/P ratio approximately 0.4-0.5), but may suppress lactation and cause electrolyte disturbances. Avoid breastfeeding during therapy.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Pregnancy can increase volume of distribution and renal clearance, potentially reducing drug concentrations. No specific dose adjustment studies for Serpasil-Esidrix #2; however, based on components: Hydrochlorothiazide may require increased dose due to enhanced clearance, but use lowest effective dose. Reserpine dosing should be minimized due to fetal risks. Avoid use in pregnancy if possible; alternative antihypertensives recommended.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Serpasil (reserpine) plus Esidrix (hydrochlorothiazide) #2 is a fixed-dose combination for hypertension. Reserpine depletes catecholamines: monitor for depression, nasal congestion, sedation, and bradycardia. Hydrochlorothiazide: check electrolytes, uric acid, glucose; avoid in anuria. Onset of reserpine action is slow (weeks) but prolonged (weeks after discontinuation). Combination may exacerbate gout and diabetes.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed; do not stop suddenly as high blood pressure may worsen.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until effects are known.,Avoid alcohol as it can increase dizziness and drowsiness.,Report symptoms of depression, slow heart rate, severe nasal congestion, or unusual bleeding/bruising.,Use sun protection as hydrochlorothiazide increases sun sensitivity.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst.,Inform all healthcare providers you are taking this medication, especially before surgery.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL-ESIDRIX #2 vs ALDORIL D30, answered by our medical review team.
SERPASIL-ESIDRIX #2 is a Antihypertensive Combination that works by Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL-ESIDRIX #2 and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL-ESIDRIX #2 is: 1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL-ESIDRIX #2 and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL-ESIDRIX #2 is classified as Category C. Serpasil (reserpine) is classified as FDA Pregnancy Category C. Reserpine crosses the placenta. First trimester: Limited human data, but animal studies suggest increased risk of sk. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.